Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Nivolumab + Ipilimumab Timing for Kidney Cancer
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial is testing two drugs, Nivolumab and Ipilimumab, to treat advanced kidney cancer. These drugs help the immune system fight cancer cells. The study aims to find better treatment strategies for patients who do not respond well to standard treatments. Nivolumab and Ipilimumab have been used in combination to treat various cancers, including metastatic melanoma and advanced renal cell carcinoma, showing promising results in improving patient outcomes.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.